Compile Data Set for Download or QSAR
maximum 50k data
Found 1627 with Last Name = 'fuller' and Initial = 'ph'
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620868((3S,4S) or (3R,4R) 4-(4-(6- chloro-2-((5-chloro-1-...)
Affinity DataIC50:  0.0800nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620916((3S,4S) or (3R,4R) 4-(4-(6- chloro-2-((5-(difluoro...)
Affinity DataIC50:  0.0800nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50584324(CHEMBL5088471)
Affinity DataIC50: <0.0800nMAssay Description:Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins follo...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620922((3R,4R)-4-(4-(6-chloro-2-((1- cyclopropyl-5-(diflu...)
Affinity DataIC50:  0.0800nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620971((3S,4S) or (3R, 4R)-4-((R) or (S)- 4-(6-chloro-2-(...)
Affinity DataIC50:  0.0880nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620720(US20230303540, Example Ex-3.1)
Affinity DataIC50:  0.0930nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620851(US20230303540, Example Ex-5.1)
Affinity DataIC50:  0.105nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620733(1-{6-chloro-2-[(1-cyclopropyl-5- methyl-1H-pyrazol...)
Affinity DataIC50:  0.106nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620974(US20230303540, Example Ex-13.1 | US20230303540, Ex...)
Affinity DataIC50:  0.116nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620858((3S,4S) or (3R,4R) 4-(4-{2-[(5- chloro-1-cycloprop...)
Affinity DataIC50:  0.170nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620778((3R,4R) or (3S,4S) 4-(4-(6-chloro- 2-((5-chloro-1-...)
Affinity DataIC50:  0.178nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620854((3S,4S) or (3R,4R) 4-(4-(2-((1- cyclopropyl-5-meth...)
Affinity DataIC50:  0.180nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620857((3S,4S) or (3R,4R) 4-(4-{2-[(1- cyclopropyl-5-meth...)
Affinity DataIC50:  0.197nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620779((R or S) 6-chloro-N-(5-chloro-1-((S) or (R) 2,2-d...)
Affinity DataIC50:  0.200nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620875(1-(6-chloro-2-{[1-(2,2-(R) or (S) difluorocyclopro...)
Affinity DataIC50:  0.200nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620868((3S,4S) or (3R,4R) 4-(4-(6- chloro-2-((5-chloro-1-...)
Affinity DataIC50:  0.212nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620734(US20230303540, Example Ex-3.15 | US20230303540, Ex...)
Affinity DataIC50:  0.218nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620731(1-(6-chloro-2-{[1-(2-hydroxy-2- methylpropyl)-1H-p...)
Affinity DataIC50:  0.221nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620734(US20230303540, Example Ex-3.15 | US20230303540, Ex...)
Affinity DataIC50:  0.227nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620977((3S,4S) or (3R, 4R)-4-(4-(2-((1- (bicyclo[1.1.1]pe...)
Affinity DataIC50:  0.267nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620893((3S,4S) or (3R,4R) 4-[4-(6- chloro-2-{[5-chloro-1-...)
Affinity DataIC50:  0.270nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620719((3S,4S or 3R,4R)-N-(1- (bicyclo[1.1.1]pentan-1-yl)...)
Affinity DataIC50:  0.279nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50609728(CHEMBL5267350)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured afte...More data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50609742(CHEMBL5286106)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assayMore data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Intervet

US Patent
LigandPNGBDBM246868(US10053465, 7 | US10065963, Compound 7 | US1012515...)
Affinity DataIC50:  0.300nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50590228(CHEMBL5172416)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser9...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50609742(CHEMBL5286106)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of LRRK2 in human PBMCs assessed as reduction in Ser95 phosphorylationMore data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620853((3S,4S) or (3R,4R) 4-(4-(2-((1- (2,2-(R) or (S) di...)
Affinity DataIC50:  0.310nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620884((3S,4S) or (3R,4R) 4-(4-{6- chloro-2-[(1-cycloprop...)
Affinity DataIC50:  0.322nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620887((3S,4S) or (3R,4R) 2-[4-({6- chloro-7-[4-(4-hydrox...)
Affinity DataIC50:  0.323nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620904((3S,4S) or (3R,4R) 4-[4-(6- chloro-2-{[1-(2,2-(R) ...)
Affinity DataIC50:  0.352nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620894((3S,4S) or (3R,4R) 4-(4-{6- chloro-2-[(5-chloro-1-...)
Affinity DataIC50:  0.381nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620751((8-syn)-3-(6-chloro-2-{[1-(2- hydroxy-2-methylprop...)
Affinity DataIC50:  0.393nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50609741(CHEMBL5284341)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assayMore data for this Ligand-Target Pair
Ligand Info
In DepthDetails PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50590227(CHEMBL5181104)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser9...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620856((3S,4S) or (3R,4R) 4-(4-(2-((5- chloro-1-cycloprop...)
Affinity DataIC50:  0.403nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620729(1-(6-chloro-2-{[1-(2-hydroxy-2- methylpropyl)-1H-p...)
Affinity DataIC50:  0.407nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620891((3S,4S) or (3R,4R) 4-[4-(6- chloro-2-{[1-(2,2-difl...)
Affinity DataIC50:  0.418nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620855((3S,4S) or (3R,4R) 4-(4-(2-((5- chloro-1-(2,2-(R) ...)
Affinity DataIC50:  0.420nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Intervet

US Patent
LigandPNGBDBM50250929(CHEMBL4066193 | US10875847, Compound 1)
Affinity DataIC50:  0.430nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620756((3R,4R) or (3S,4S) 4-(4-{6-chloro-2- [(1,5-dimethy...)
Affinity DataIC50:  0.438nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620777((3R,4R) or (3S,4S) 4-(4-(6-chloro-2- ((5-chloro-1-...)
Affinity DataIC50:  0.440nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620852((3S,4S) or (3R,4R) 4-(4-(2-((1- (2,2-(R) or (S) di...)
Affinity DataIC50:  0.450nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Intervet

US Patent
LigandPNGBDBM50021656(BARICITINIB | INCB-028050 | LY-3009104 | US1011290...)
Affinity DataIC50:  0.470nMMore data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620746((8-syn)-3-{6-chloro-2-[(1- cyclopropyl-5-methyl-1H...)
Affinity DataIC50:  0.486nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM620730(1-(6-chloro-2-{[5-chloro-1-(2- hydroxy-2-methylpro...)
Affinity DataIC50:  0.488nMAssay Description:The LRRK2 kinase activity reported herein as IC50 values was determined with LanthaScreen technology from Life Technologies Corporation (Carlsbad, CA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM257207(US9493440, 51)
Affinity DataIC50:  0.5nMAssay Description:Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured afte...More data for this Ligand-Target Pair
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359544(4-{(6R or S)-1-({2- chloro-6-[1- (difluoromethyl)c...)
Affinity DataIC50:  0.5nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359569((R or S)-4-(1-(2- chloro-6-(1- (trifluoromethyl)cy...)
Affinity DataIC50:  0.5nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear receptor ROR-gamma(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM359568((R or S)-4-(1-(2- chloro-6-(1- (trifluoromethyl)cy...)
Affinity DataIC50:  0.5nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 1627 total ) | Next | Last >>
Jump to: